BIRC5 and neoplasm: Survivin, an anti-apoptotic protein, is highly expressed in most cancers and is associated with chemotherapy resistance, increased tumor recurrence, and shorter patient survival, making anti-survivin therapy an attractive cancer treatment strategy for use with a chemotherapeutic regimen [36–38].